Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
AUTHORS
Toh
S ,
Hampp
C ,
Reichman
ME ,
Graham
DJ ,
Balakrishnan
S ,
Pucino
F ,
Hamilton
J ,
Lendle
S ,
Iyer
A ,
Rucker
M ,
Pimentel
M ,
Nathwani
N ,
Griffin
MR ,
Brown
NJ ,
Fireman
BH ,
. Annals of internal medicine. 2016 4 26; ().
- NIHMSID: 0372351
ABSTRACT
Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.
Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents.
Tags: Faculty Publications 2016